Telomir Competitors
| TELO Stock | 1.34 0.02 1.52% |
Telomir Pharmaceuticals vs INmune Bio Correlation
Very weak diversification
The correlation between Telomir Pharmaceuticals Common and INMB is 0.47 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Telomir Pharmaceuticals Common and INMB in the same portfolio, assuming nothing else is changed.
Moving against Telomir Stock
| 0.59 | TBPH | Theravance Biopharma | PairCorr |
| 0.57 | 000788 | PKU HealthCare Corp | PairCorr |
| 0.45 | GSK | GlaxoSmithKline PLC ADR | PairCorr |
| 0.45 | PFE | Pfizer Inc Sell-off Trend | PairCorr |
| 0.43 | MRK | Merck Company | PairCorr |
Telomir Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Telomir Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Telomir and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Telomir Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Telomir Stock performing well and Telomir Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Telomir Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MDCX | 3.65 | (0.88) | 0.00 | (1.39) | 0.00 | 6.77 | 18.68 | |||
| GNTA | 5.94 | (0.63) | 0.00 | (0.22) | 0.00 | 6.96 | 138.40 | |||
| IPSC | 5.81 | 2.47 | 0.38 | 1.75 | 4.52 | 13.95 | 55.97 | |||
| BRNS | 3.18 | (0.94) | 0.00 | (1.04) | 0.00 | 5.71 | 24.01 | |||
| CVM | 4.59 | (0.62) | 0.00 | (0.27) | 0.00 | 10.19 | 25.92 | |||
| KPTI | 3.60 | 0.03 | 0.01 | 0.09 | 4.15 | 8.02 | 18.05 | |||
| SKYE | 4.86 | (0.36) | 0.00 | (0.14) | 0.00 | 10.19 | 24.11 | |||
| COEP | 3.13 | (0.12) | 0.00 | (0.04) | 0.00 | 7.44 | 22.14 | |||
| EQ | 5.86 | 0.05 | 0.01 | 0.13 | 6.60 | 19.26 | 43.07 | |||
| INMB | 3.51 | (0.23) | 0.00 | (0.05) | 0.00 | 6.81 | 21.68 |
Cross Equities Net Income Analysis
Compare Telomir Pharmaceuticals and related stocks such as Medicus Pharma, Genenta Science SpA, and Century Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNTA | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (5.6 M) | (5.5 M) | (8.5 M) | (11.6 M) | (8.9 M) | (8 M) | (8.4 M) |
| IPSC | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (53.6 M) | (95.8 M) | (130.9 M) | (136.7 M) | (126.6 M) | (145.6 M) | (152.8 M) |
| BRNS | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (17.7 M) | (50.9 M) | 5.3 M | (73.3 M) | (61.1 M) | (55 M) | (57.7 M) |
| CVM | (2.9 M) | (15.5 M) | (9.2 M) | (27.4 M) | (34.7 M) | (11.5 M) | (14.4 M) | (31.8 M) | (24.7 M) | (32.2 M) | (39.2 M) | (38.3 M) | (32.4 M) | (26.9 M) | (25.4 M) | (22.9 M) | (21.7 M) |
| KPTI | (10.3 M) | (10.3 M) | (15.9 M) | (33.9 M) | (75.8 M) | (118.2 M) | (109.6 M) | (129 M) | (178.4 M) | (199.6 M) | (196.3 M) | (124.1 M) | (165.3 M) | (143.1 M) | (76.4 M) | (68.8 M) | (72.2 M) |
| SKYE | 4.5 K | 4.5 K | 4.5 K | (120.4 K) | (2.7 M) | (4.8 M) | (3.2 M) | (3.1 M) | (19.2 M) | 1.1 M | (6.6 M) | (8.5 M) | (19.5 M) | (37.6 M) | (26.6 M) | (23.9 M) | (22.7 M) |
| COEP | 2.6 M | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (2.2 K) | (9.2 M) | (13.4 M) | (37.6 M) | (21.3 M) | (10.9 M) | (9.8 M) | (10.3 M) |
| EQ | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (13.2 M) | (25.6 M) | (29.8 M) | (39 M) | (62.4 M) | (13.3 M) | (8.1 M) | (7.3 M) | (7.6 M) |
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (277 K) | (831 K) | (12.4 M) | (7.7 M) | (12.1 M) | (30.3 M) | (28.6 M) | (30 M) | (42.1 M) | (37.9 M) | (36 M) |
Telomir Pharmaceuticals and related stocks such as Medicus Pharma, Genenta Science SpA, and Century Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Telomir Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Telomir Pharmaceuticals Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Telomir Pharmaceuticals Competitive Analysis
The better you understand Telomir Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Telomir Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Telomir Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Telomir Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Telomir Pharmaceuticals Competition
Telomir Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Telomir Pharmaceuticals in relation to its competition. Telomir Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Telomir Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Telomir Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Telomir Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Telomir Pharmaceuticals position
In addition to having Telomir Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Market Funds Thematic Idea Now
Money Market Funds
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Telomir Pharmaceuticals Correlation with its peers. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Telomir Pharmaceuticals is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals' market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.